147 related articles for article (PubMed ID: 2504987)
1. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy.
Martinelli R; Noblat AC; Brito E; Rocha H
Kidney Int; 1989 May; 35(5):1227-33. PubMed ID: 2504987
[TBL] [Abstract][Full Text] [Related]
2. Use of praziquantel in patients with schistosomiasis mansoni previously treated with oxamniquine and/or hycanthone: resistance of Schistosoma mansoni to schistosomicidal agents.
de Souza Dias LC; de Jesus Pedro R; Deberaldini ER
Trans R Soc Trop Med Hyg; 1982; 76(5):652-9. PubMed ID: 7179419
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of oral therapy of mansonial schistosomiasis in the Sudan using single and multiple doses of hycanthone and oxamniquine drugs.
Magzoub M; Adam SE
J Pharmacol Exp Ther; 1978 Aug; 206(2):382-7. PubMed ID: 682120
[No Abstract] [Full Text] [Related]
4. The influence of anti-parasitic therapy on the course of the glomerulopathy associated with Schistosomiasis mansoni.
Martinelli R; Pereira LJ; Rocha H
Clin Nephrol; 1987 May; 27(5):229-32. PubMed ID: 3109794
[TBL] [Abstract][Full Text] [Related]
5. [Drug therapy of mansoni schistosomiasis].
Zeitune JM; Ramos SR; Sugmyama LC; Côrte AA
Arq Gastroenterol; 1980; 17(2):88-95. PubMed ID: 7213141
[TBL] [Abstract][Full Text] [Related]
6. The treatment of schistosomiasis mansoni in Murang'a District, Kenya: a double blind controlled trial of three hycanthone regimens and oxamniquine.
Rees PH; Bowry HN; Roberts JM; Thuku JJ
Am J Trop Med Hyg; 1975 Sep; 24(5):823-6. PubMed ID: 1190368
[No Abstract] [Full Text] [Related]
7. [Resistance to hycanthone and oxamniquine in patients with a clinical hepato-intestinal form of schistosomiasis].
Guimarães RX; Tchakerian A; Dias LC; de Almeida FM; Vilela MP; Cabeca M; Takeda AK
AMB Rev Assoc Med Bras; 1979 Feb; 25(2):48-50. PubMed ID: 314642
[No Abstract] [Full Text] [Related]
8. Serum enzymatic changes in patients with schistosomiasis treated with oxamniquine or hycanthone. Comparative study.
Saéz-Alquézar A; Ohtsuki N; Sette Júnior H; Magnanelli AC; Raia S; da Silva LC
Rev Inst Med Trop Sao Paulo; 1980; 22(1 Suppl 4):105-10, 225-31. PubMed ID: 7455503
[No Abstract] [Full Text] [Related]
9. Effect of chemotherapy on experimental pulmonary schistosomiasis.
de Almeida MA; Andrade ZA
Am J Trop Med Hyg; 1983 Sep; 32(5):1049-54. PubMed ID: 6625060
[TBL] [Abstract][Full Text] [Related]
10. Curative chemotherapy and resistance to reinfection in murine schistosomiasis.
Andrade ZA; Azevedo de Brito P
Am J Trop Med Hyg; 1982 Jan; 31(1):116-21. PubMed ID: 7058973
[TBL] [Abstract][Full Text] [Related]
11. Experimental chemotherapy of Schistosoma curassoni in mice.
Vercruysse J; Southgate VR; Rollinson D; Hilderson H
Parasitol Res; 1989; 75(7):559-62. PubMed ID: 2771923
[TBL] [Abstract][Full Text] [Related]
12. Control of Schistosoma mansoni transmission by chemotherapy in St. Lucia. I. Results in man.
Cook JA; Jordan P; Bartholomew RK
Am J Trop Med Hyg; 1977 Sep; 26(5 Pt 1):887-93. PubMed ID: 907051
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Schistosoma mansoni infection with oxamniquine in Riyadh, Saudi Arabia.
Al-Aska AK
Trop Med Parasitol; 1985 Dec; 36(4):213-4. PubMed ID: 3937212
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with primary immune-complex type mesangiocapillary glomerulonephritis (MCGN) in Cape Town South Africa.
Okpechi IG; Dlamini TA; Duffield M; Rayner BL; Moturi G; Swanepoel CR
PLoS One; 2014; 9(11):e113302. PubMed ID: 25411791
[TBL] [Abstract][Full Text] [Related]
15. Fatal hepatic necrosis in association with hycanthone.
Hatchuel W
S Afr Med J; 1978 Nov; 54(20):808. PubMed ID: 741319
[No Abstract] [Full Text] [Related]
16. Observations of the treatment of mansoni schistosomiasis with oxamniquine: efficacy in children and in persistent salmonellosis; resistance of a strain of Schistosoma mansoni; hepatic toxicity and neurological side effects.
Pedro Rde J; de Souza Dias LC; Amato Neto V; de Carvalho SA
Rev Inst Med Trop Sao Paulo; 1980; 22(1 Suppl 4):32-6, 148-52. PubMed ID: 7455507
[No Abstract] [Full Text] [Related]
17. Clinical course of focal segmental glomerulosclerosis associated with hepatosplenic schistosomiasis mansoni.
Martinelli R; Pereira LJ; Brito E; Rocha H
Nephron; 1995; 69(2):131-4. PubMed ID: 7723893
[TBL] [Abstract][Full Text] [Related]
18. Schistosomiasis-associated glomerulopathy: Clinical aspects, pathological characteristics, and renal outcomes
.
Neves PDMM; Jorge LB; Cavalcante LB; Malheiros D; Woronik V; Dias CB
Clin Nephrol; 2020 May; 93(5):251-261. PubMed ID: 32228829
[TBL] [Abstract][Full Text] [Related]
19. Observations on the treatment of mansoni schistosomiasis with oxamniquine.
Pedro RD; Dias LC; Amato Neto V; De Carvalho SA
Rev Bras Pesqui Med Biol; 1979 Jun; 12(2-3):207-11. PubMed ID: 515473
[No Abstract] [Full Text] [Related]
20. Nephrotic syndrome associated with Schistosoma mansoni infection.
Agarwal BN
Del Med J; 1993 Jul; 65(7):429-32. PubMed ID: 8354416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
